Serum Adiponectin Level As a Predictor of Subclinical Cushing's Syndrome in Patients with Adrenal Incidentaloma

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2016 Sep 23

PMID 27656211

Citations 2

Authors

Asli Dogruk Unal

Semra Ayturk

Derya Aldemir

Neslihan Bascil Tutuncu

Affiliations

Soon will be listed here.

Abstract

Subclinical Cushing's syndrome (SCS) is a condition of slight but chronic cortisol excess in patients with adrenal incidentaloma (AI) without typical signs and symptoms of Cushing's syndrome. Adiponectin has potent roles in modulating energy balance and metabolic homeostasis and acts in opposition to glucocorticoids. This study aimed to evaluate adiponectin level in SCS and nonfunctional AI (NAI) patients and its relation with metabolic parameters. Patients with AI (n = 40) and metabolically healthy controls (n = 30) were included. In AI patients and controls, detailed medical history assessment, physical examinations, anthropometric measurements, and laboratory measurements were performed. Age, body mass index, waist circumference, and lipid profiles were significantly higher and waist-to-hip ratio and adiponectin level were significantly lower in the AI patients than in the controls. The midnight cortisol and urinary free cortisol levels were significantly higher in the SCS patients (n = 8) than in the NAI patients (n = 32). Adiponectin level of the SCS group was significantly lower than those of the NAI and control groups. The sensitivity and specificity for an adiponectin level of ≤13.00 ng/mL in predicting the presence of SCS were 87.5% and 77.4%, respectively. In conclusion, adiponectin is valuable in predicting the presence of SCS in AI patients.

Citing Articles

The role of selected adipokines in tumorigenesis and metabolic disorders in patients with adrenal tumors.

Babinska A, Kmiec P, Sworczak K Arch Med Sci. 2023; 19(2):467-477.

PMID: 37034534 PMC: 10074290. DOI: 10.5114/aoms.2020.93486.

Predictive Factors of Functioning Adrenal Incidentaloma: A 15-Year Retrospective Study.

Muangnoo N, Manosroi W, Leelathanapipat N, Meejun T, Chowchaiyaporn P, Teetipsatit P Medicina (Kaunas). 2022; 58(5).

PMID: 35630017 PMC: 9144654. DOI: 10.3390/medicina58050597.

References

Nieman L . Cushing's syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol. 2015; 173(4):M33-8. PMC: 4553096. DOI: 10.1530/EJE-15-0464. View

Swiatkowska-Stodulska R, Skibowska-Bielinska A, Wisniewski P, Sworczak K . Activity of selected coagulation factors in overt and subclinical hypercortisolism. Endocr J. 2015; 62(8):687-94. DOI: 10.1507/endocrj.EJ14-0539. View

Kishida K, Funahashi T, Shimomura I . Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab. 2014; 28(1):119-30. DOI: 10.1016/j.beem.2013.08.006. View

Giordano R, Marinazzo E, Berardelli R, Picu A, Maccario M, Ghigo E . Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur J Endocrinol. 2010; 162(4):779-85. DOI: 10.1530/EJE-09-0957. View

Kadowaki T, Yamauchi T . Adiponectin and adiponectin receptors. Endocr Rev. 2005; 26(3):439-51. DOI: 10.1210/er.2005-0005. View

Fallo F, Scarda A, Sonino N, Paoletta A, Boscaro M, Pagano C . Effect of glucocorticoids on adiponectin: a study in healthy subjects and in Cushing's syndrome. Eur J Endocrinol. 2004; 150(3):339-44. DOI: 10.1530/eje.0.1500339. View

Pecori Giraldi F, Pivonello R, Ambrogio A, De Martino M, De Martin M, Scacchi M . The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol (Oxf). 2007; 66(2):251-7. DOI: 10.1111/j.1365-2265.2006.02717.x. View

Rossi R, Tauchmanova L, Luciano A, Di Martino M, Battista C, del Viscovo L . Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab. 2000; 85(4):1440-8. DOI: 10.1210/jcem.85.4.6515. View

MacDougald O, Mandrup S . Adipogenesis: forces that tip the scales. Trends Endocrinol Metab. 2001; 13(1):5-11. DOI: 10.1016/s1043-2760(01)00517-3. View

10.

Li S, Shin H, Ding E, van Dam R . Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009; 302(2):179-88. DOI: 10.1001/jama.2009.976. View

11.

Terzolo M, Bovio S, Pia A, Conton P, Reimondo G, DallAsta C . Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur J Endocrinol. 2005; 153(2):307-15. DOI: 10.1530/eje.1.01959. View

12.

Ermetici F, Malavazos A, Corbetta S, Morricone L, DallAsta C, Corsi M . Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma. Metabolism. 2007; 56(5):686-92. DOI: 10.1016/j.metabol.2006.12.018. View

13.

Chiodini I, Morelli V, Salcuni A, Eller-Vainicher C, Torlontano M, Coletti F . Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab. 2010; 95(6):2736-45. DOI: 10.1210/jc.2009-2387. View

14.

Liu M, Liu F . Transcriptional and post-translational regulation of adiponectin. Biochem J. 2009; 425(1):41-52. DOI: 10.1042/BJ20091045. View

15.

Phillips S, Kung J . Mechanisms of adiponectin regulation and use as a pharmacological target. Curr Opin Pharmacol. 2010; 10(6):676-83. DOI: 10.1016/j.coph.2010.08.002. View

16.

Sereg M, Szappanos A, Toke J, Karlinger K, Feldman K, Kaszper E . Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study. Eur J Endocrinol. 2009; 160(4):647-55. DOI: 10.1530/EJE-08-0707. View

17.

Di Dalmazi G, Pasquali R, Beuschlein F, Reincke M . Subclinical hypercortisolism: a state, a syndrome, or a disease?. Eur J Endocrinol. 2015; 173(4):M61-71. DOI: 10.1530/EJE-15-0272. View

18.

Tauchmanova L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Fazio S . Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002; 87(11):4872-8. DOI: 10.1210/jc.2001-011766. View

19.

Ouchi N, Walsh K . Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007; 380(1-2):24-30. PMC: 2755046. DOI: 10.1016/j.cca.2007.01.026. View

20.

Terzolo M, Pia A, Reimondo G . Subclinical Cushing's syndrome: definition and management. Clin Endocrinol (Oxf). 2011; 76(1):12-8. DOI: 10.1111/j.1365-2265.2011.04253.x. View